Lorus Therapeutics Receives 600 Thousand From Escrow Account: related news

Lorus Therapeutics Receives $600 Thousand From Escrow Account

TORONTO, July 16 /CNW/ - Lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that the Corporation has received the $600 thousand originally held in escrow in connection with Lorus' corporate reorganization completed on July 10, 2007. The Corporation has received total net proceeds of $6.9 million in non-dilutive financing as part of this transaction.

Lorus Therapeutics Receives $600 Thousand From Escrow Account

TORONTO, July 16 /CNW/ - Lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that the Corporation has received the $600 thousand originally held in escrow in connection with Lorus' corporate reorganization completed on July 10, 2007. The Corporation has received total net proceeds of $6.9 million in non-dilutive financing as part of this transaction.

Lorus Therapeutics Receives $600 Thousand From Escrow Account

TORONTO, July 16 /CNW/ - Lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that the Corporation has received the $600 thousand originally held in escrow in connection with Lorus' corporate reorganization completed on July 10, 2007. The Corporation has received total net proceeds of $6.9 million in non-dilutive financing as part of this transaction.

Lorus Therapeutics Receives $600 Thousand From Escrow Account

TORONTO, July 16 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that the Corporation has received the $600 thousand originally held in escrow in connection with Lorus' corporate reorganization completed on July 10, 2007. The Corporation has received total net proceeds of $6.9 million in non-dilutive financing as part of this transaction.

Lorus Therapeutics Receives $600 Thousand From Escrow Account

TORONTO, July 16, 2008 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that the Corporation has received the $600 thousand originally held in escrow in connection with Lorus' corporate reorganization completed on July 10, 2007. The Corporation has received total net proceeds of $6.9 million in non-dilutive financing as part of this transaction.

Lorus Therapeutics Receives $600 Thousand From Escrow Account

PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that the Corporation has received the

Lorus Therapeutics Receives $600 Thousand From Escrow Account

Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)

Lorus Therapeutics Receives $600K From Escrow Account

(RTTNews) - Lorus Therapeutics Inc. (LOR.V, LRP) said it received $600 thousand held in escrow in connection with its corporate reorganization completed on July 10, 2007. The company said it received total net proceeds of $6.9 million in non-dilutive financing as part of this transaction.

Lorus Therapeutics Receives $600 Thousand From Escrow Account

Hier finden Sie Nachrichten zu Ihrem Suchbegriff - Sie können den Zeitraum angeben oder auch Suchbegriffe kombinierenErweiterte Suche |

Lorus Therapeutics Inc announces USD600,000 from Escrow Account

Lorus Therapeutics Inc (TSX: LOR, AMEX: LRP), a biopharmaceutical company specialising in the research and development of pharmaceutical products and technologies for the management of cancer, declared on 16 July the receipt of USD600,000, originally held in escrow in connection with the company's corporate reorganisation which was completed on 10 July 2007.

Too Easy For Bank Accounts To Spring a Leak

The NYTimes has a cautionary tale of automated clearing house fraud. Parties unknown siphoned money from an individual's bank account. Nothing too unusual there, except that it was an elite private banking account at JPMorgan Chase, and the account holder is out $250K — the bank will only cover $50K of his loss. The $300K came out of the account in small transactions over 15 months. The bank offered no recourse except to open a new account, a large hassle given that the account is more than 20 years old and its holder writes a thousand checks a month. The article details how the spread of electronic settlements between banks has given rise to growing automated clearing house fraud — if anyone gets hold of the magic combination of account number and bank routing number, and once has permission to withdraw funds, all bets are off.

Lorus Therapeutics Announces Allowance of New United States Patent for its Anticancer Drug LOR-2040

Lorus Therapeutics Inc. (TSX:LOR)(AMEX:LRP) ("Lorus"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced the allowance of a new patent from the United States Patent and Trademark Office for its clinical-stage anticancer drug LOR-2040.

Lorus Therapeutics Announces Allowance Of New United States Patent For Its Anticancer Drug LOR-2040

Toronto, Canada - Lorus Therapeutics Inc. ("Lorus"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, recently announced the allowance of a new patent from the United States Patent and Trademark Office for its clinical-stage anticancer drug LOR-2040.

Lorus receives U.S. patent for LOR-2040

Lorus Therapeutics Inc. has received a new patent from the United States Patent and Trademark Office for its clinical-stage anti-cancer drug LOR-2040.

Lorus receives another Virlizin patent for Mexico

Lorus Therapeutics Inc. has made progress in the Virulizin development program, including the publication of two research studies on the Virulizin mode of action and the issuance of a new patent for Virulizin in Mexico.

Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

Novelos Therapeutics Receives 6th U.S. Patent

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos was issued U.S. Pat. No. 7,371,411 by the U.S. Patent and Trademark Office extending the composition and method of use claims relating to NOV-002, Novelos' lead compound in an ongoing pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track. NOV-002 has also demonstrated positive results in Phase 2 trials for other oncology indications.

Novelos Therapeutics Receives 6th U.S. Patent

NEWTON, Mass.--(BUSINESS WIRE)--Novelos Therapeutics, Inc. (OTCBB: NVLT - News), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos was issued U.S. Pat. No. 7,371,411 by the U.S. Patent and Trademark Office extending the composition and method of use claims relating to NOV-002, Novelos

Novelos Therapeutics Receives 6th U.S. Patent

NEWTON, Mass.--(BUSINESS WIRE)--June 30, 2008 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos was issued U.S. Pat. No. 7,371,411 by the U.S. Patent and Trademark Office extending the composition and method of use claims relating to NOV-002, Novelos' lead compound in an ongoing pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track. NOV-002 has also demonstrated positive results in Phase 2 trials for other oncology indications.

Cytori Therapeutics Receives US Patent For Celution System-Based Devices And Methods

Cytori (CYTX) Receives U.S. Patent Allowance for Protecting Cosmetic & Reconstructive Surgery Product Line

Tobira Therapeutics Inc. Receives US Patent Ob...

PRINCETON, N.J. and SAN DIEGO, Aug. 18 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to the research and product discovery against life-threatening and life-altering infectious diseases, today announced the issuance of Patent No. 7,371,772 B2 by the U.S. Patent and Trademark Office, covering the use of TBR-652, a CCR5 antagonist currently in Phase I development for the treatment of HIV-1 infection in adults.

Tobira Therapeutics Inc. Receives US Patent for TBR-652

PRINCETON, N.J. and SAN DIEGO, Aug. 18 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to the research and product discovery against life-threatening and life-altering infectious diseases, today announced the issuance of Patent No. 7,371,772 B2 by the U.S. Patent and Trademark Office, covering the use of TBR-652, a CCR5 antagonist currently in Phase I development for the treatment of HIV-1 infection in adults.

Authernative Granted U.S. Patent

Authernative, Inc., developer of user and transaction authentication and identity management technologies, announced that the United States Patent & Trademark Office has granted the company a patent for a private and secure financial transactions method. The patent describes an enhanced security and fraud protection system, which enables financial account holders to perform secure financial transactions with or without disclosing private financial or personal information to merchants or sellers. The method describes a transaction-processing architecture for performing secure in-person, offline, online, or mobile financial transactions with the direct participation of the account holder's financial account. The patent also introduces a random partial PIN/password recognition algorithm to authenticate the account holder.

Escrow payment coupon books shipped out on July 23

MARION - Real estate tax escrow payment coupon books were mailed on Wednesday, July 23, 2008, according to Marion County Chief Deputy Treasurer, Jan Draper. Taxpayers who have not received their escrow payment coupon books are urged to contact the Marion County Treasurer's Office at 740-223-4030.

Search took 0.08 seconds.